Treats heartburn and other symptoms associated GERD. ANDA 208511, held by Macleods Pharms. Esomeprazole Magnesium.
As of Nov 16, 2026, ANDA 208511 (Esomeprazole Magnesium), held by Macleods Pharms, was first approved by FDA on Oct 23, 2024, with 0 approved supplements and 0 published complete response letters.
Esomeprazole magnesium delayed-release capsules are a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 23, 2024 | Original application | Approved | None posted |
| Esomeprazole MagnesiumEQ 20MG BASE · capsule, delayed rel pellets;oral | Esomeprazole Magnesium | Discontinued |
| Esomeprazole MagnesiumEQ 40MG BASE · capsule, delayed rel pellets;oral | Esomeprazole Magnesium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters